FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:1617-1618 October 13, 2005 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Pass, H. I. PubMed Citation

In this issue of the Journal, Pass et al.¹ remind us yet again that the fallout from the once uncontrolled use of asbestos will remain with us for years to come. Thankfully, primary prevention of mesothelioma and the far more prevalent consequence of exposure to asbestos — carcinoma of the lung — has been aggressively pursued to varying degrees in all developed countries: most potential sources of human exposure have now been removed or encapsulated, and the introduction of additional asbestos severely curtailed or banned outright. Unfortunately, among the millions exposed occupationally in the past who remain at high risk . . . [Full Text of this Article]

Source Information

From the Yale University School of Medicine, New Haven, Conn.

This article has been cited by other articles:

• Grigoriu, B.-D., Scherpereel, A., Devos, P., Chahine, B., Letourneux, M., Lebailly, P., Gregoire, M., Porte, H., Copin, M.-C., Lassalle, P. (2007). Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment. Clin. Cancer Res. 13: 2928-2935 [Abstract] [Full Text]  
• Scherpereel, A., Grigoriu, B., Conti, M., Gey, T., Gregoire, M., Copin, M.-C., Devos, P., Chahine, B., Porte, H., Lassalle, P. (2006). Soluble Mesothelin-related Peptides in the Diagnosis of Malignant Pleural Mesothelioma. Am. J. Respir. Crit. Care Med. 173: 1155-1160 [Abstract] [Full Text]